Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

被引：0

作者：

Kelly-Anne Phillips

Julie Aldridge

Karin Ribi

Zhuoxin Sun

Alastair Thompson

Vernon Harvey

Beat Thürlimann

Fatima Cardoso

Olivia Pagani

Alan S. Coates

Aron Goldhirsch

Karen N. Price

Richard D. Gelber

Jürg Bernhard

机构：

[1] The University of Melbourne,Peter MacCallum Cancer Centre

[2] Dana-Farber Cancer Institute,IBCSG Statistical Center

[3] IBCSG Coordinating Center,Ninewells Hospital

[4] University of Dundee,Breast Center

[5] Auckland City Hospital,Department of Medical Oncology

[6] Australian New Zealand Breast Cancer Trials Group,Oncology Institute of Southern Switzerland

[7] Kantonsspital,Department of Medicine

[8] Swiss Group for Clinical Cancer Research (SAKK),IBCSG Statistical Center, Frontier Science and Technology Research Foundation

[9] Jules Bordet Institute,IBCSG Statistical Center, Frontier Science and Technology Research Foundation

[10] Ospedale Italiano,Department of Medical Oncology

[11] International Breast Cancer Study Group,undefined

[12] University of Sydney,undefined

[13] European Institute of Oncology,undefined

[14] Oncology Institute of Southern Switzerland,undefined

[15] Dana-Farber Cancer Institute,undefined

[16] Dana-Farber Cancer Institute,undefined

[17] IBCSG Coordinating Center,undefined

[18] Inselspital,undefined

[19] Bern University Hospital,undefined

来源：

Breast Cancer Research and Treatment | 2011年 / 126卷

关键词：

Cognitive function; Breast cancer; Aromatase inhibitor; Tamoxifen; Letrozole; Quality of life;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Endocrine therapy for breast cancer may affect cognition. The purpose of this study was to examine whether cognitive function improves after cessation of adjuvant endocrine therapy. Change in cognitive function was assessed in 100 postmenopausal breast cancer patients in the BIG 1-98 trial, who were randomized to receive 5 years of adjuvant tamoxifen or letrozole alone or in sequence. Cognitive function was evaluated by computerized tests during the fifth year of trial treatment (Y5) and 1 year after treatment completion (Y6). Cognitive test scores were standardized according to age-specific norms and the change assessed using the Wilcoxon signed-rank test. There was significant improvement in the composite cognitive function score from Y5 to Y6 (median of change = 0.22, effect size = 0.53, P < 0.0001). This improvement was consistent in women taking either tamoxifen or letrozole at Y5 (P = 0.0006 and P = 0.0002, respectively). For postmenopausal patients who received either adjuvant letrozole or tamoxifen alone or in sequence, cognitive function improved after cessation of treatment.

引用

页码：221 / 226

页数：5

共 43 条

[1]

McCarty KS(1983)Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast Ann Surg 197 123-127

[2]

Silva JS(2010)Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial J Clin Oncol 28 1294-1300

[3]

Cox EB(2009)Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study Psychooncology 18 811-821

[4]

Schilder CM(2006)Cognitive impairment associated with adjuvant therapy in breast cancer Psychooncology 15 422-430

[5]

Seynaeve C(2004)Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study Psychooncology 13 61-66

[6]

Beex WB(2010)Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomised trial Breast 19 388-395

[7]

Collins B(2008)Effects of anastrozole on cognitive performance in postmenopausal women: a randomized, double-blind chemoprevention trial (IBIS II) Lancet Oncol 9 953-961

[8]

Mackenzie J(2005)A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747-2757

[9]

Stewart A(2009)Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 766-776

[10]

Bender CM(2006)Assessing cognitive function in cancer patients Support Care Cancer 14 1111-1118

← 1 2 3 4 5 →